Navigation Links
FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane
Date:6/23/2008

with cancer-related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward-looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for Genasense(R) from the U.S. Food and Drug Administration ("FDA") or European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its products or product candidates;

-- the Company's ability to enter into and successfully execute license and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow projections, the Company's ability to obtain sufficient financing to maintain the Company's planned operations, or the Company's risk of bankruptcy if it is unsuccessful in obtaining such financing or in securing shareholder approval to increase the number of
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
2. iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix
3. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
4. eRT Announces the Availability of the Suicidality Monitoring System(TM) For Clinical Trials
5. The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
6. Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY(TM) Eradicates MRSA From Chronic Venous Ulcers
7. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
8. Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials
9. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
10. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
11. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... , CHAPEL HILL, N.C., Nov. 25 /PRNewswire/ -... Prabhavathi Fernandes, president and chief execut...t Annual Health Care Conference at 8:50 a.m. EST, ...New York City. Dr. Fernandes will provide an over...cal programs for the treatment of drug-resistant p...
(Date:11/25/2009)... , NEW YORK, Nov. 25 Repor...eport is available in its catalogue: ,, Intran...is http://www.reportlinker.com/p0164267/Intranas... ,, The US intranasal drug delivery market is ...s from the delivery of conventional local therapeu...
(Date:11/25/2009)... , FRAMINGHAM, Mass. and SYDNEY, Nov. 25 /PRNe... (Nasdaq: HTWR ; ASX: HIN), a leading innovator a...tory support technologies revolutionizing the trea...hat it is scheduled to make an investor presentati...nference at 8:00 am EST on Wednesday, December 2, ...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City 2New Bisphenol a Study Has Many Limitations but No Clear Conclusions 58912 1New Bisphenol a Study Has Many Limitations but No Clear Conclusions 58912 2New Bisphenol a Study Has Many Limitations but No Clear Conclusions 58912 3News briefs from the October issue of Chest 58908 1News briefs from the October issue of Chest 58908 2HEAL Africas Founders Conduct Nationwide Tour to Share Best Practices for Rebuilding Congo 58904 1HEAL Africas Founders Conduct Nationwide Tour to Share Best Practices for Rebuilding Congo 58904 2HEAL Africas Founders Conduct Nationwide Tour to Share Best Practices for Rebuilding Congo 58904 3
...ain, Sept. 25 Five-year follow-up overall,surviva...ncer Trial) study,show that oral chemotherapy Xelo...t standard treatment - intravenous bolus 5-FU/LV (...tment of Dukes, C colon cancer. These,data were pr...ce (ECCO) in,Barcelona, Spain. Results show five-...
... Hearing Loss Program With Novel SiRNA Approaches ...g Candidate, AHLI-11, For The, Prevention Of Che...ge, FREMONT, Calif., Sept. 24 Quark Pharmaceutic...ny focused on discovering and,developing novel RNA...that,it has signed a collaboration agreement with ...
Other Medicine Technology:Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting 2Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting 3Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting 4Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss 2Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss 3
(Date:11/27/2009)...ch firm Replikins Ltd. today issued its latest bio... It shows that the lethality of the virus has drop...us,s current outbreak in the spring of 2009 to res...1). The H1N1 infectivity count, however, remains i...) November 27, 2009 -- Biotech firm Replikins Ltd....
(Date:11/27/2009)...v. 27 Preventing diseas...rtunately every year, new vaccines are being added...nes boost immunity for the same period of time? An...ded to keep immunity strong? ,, In this month...n Academy of Pediatrics, Michael Pichichero MD, Di...
(Date:11/27/2009)...are Holdings has announced that it has become a na... the largest nonprofit organizations dedicated to ... Delray Beach, FL (Vocus) ...B: XCHO), a company specializing in the marketing ...ducts, has announced today that is has become a na...
(Date:11/27/2009)...TTLE, Nov. 27 Allrecipes.com , ...nksgiving traffic numbers, with more than 2.8 mill...g a clear picture of what was served on the bigges...ng meal in 2009 weighed in at 2,225 calories per s...t. According to the Allrecipes site, Sweet Potato...
(Date:11/27/2009)...alist manufacturers who use medical load cells at ... dollars by bringing in technology partner Flintec...f pro-active medical manufacturers are calling in ...their projects, ensuring that progress will not be...tially outdated technology. , ...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...a,s Baby Boomers and Seniors Are Target Audiences ...EJO, Calif., Feb. 4 Bausch & Lomb, the global...vertising campaign has been launched in six Florid...rystalens, which is a product of Bausch & Lomb...
...SHINGTON, Feb. 4 "Patients, nurses, and the Broad...n to move into Ashburn was,denied," said Kathy McG...,Association/National Nurses Organizing Committee,...re,in the name of profits, and of shortchanging th...
... Solid 30 Percent Year-Over-Year...ve Strong 2008 Year End Results , ...9 -- Despite an economic environment that has prov...e the current economic environment, Lumension Se...
... A new website that displays a w...Spanish speakers to strawberries produced to Bigfo...prises. , Washington, DC ... whole new way, launched today. , ,From Spanish sp...
... Reid Supply Company,s President...esigned and improved company web site, as well as ...al products catalog. Both ReidSupply.com and the c...8, Reid Supply focuses on enhancing the Customer e...
...UIS, Feb. 3 Ther-Rx Corporation, a subsidiary of ...uing a voluntary nationwide recall of prescription...tified below (all lots within their expiration dat...ons that did not sufficiently comply with current ...
Other Medicine News:Health News:Bausch & Lomb's Crystalens to be Featured in Florida Advertising Campaign. 2Health News:Bausch & Lomb's Crystalens to be Featured in Florida Advertising Campaign. 3Health News:Lumension Expands Global Footprint, Extends Leadership in Endpoint Security and Unveils New Brand Identity 2Health News:Lumension Expands Global Footprint, Extends Leadership in Endpoint Security and Unveils New Brand Identity 3Health News:Lumension Expands Global Footprint, Extends Leadership in Endpoint Security and Unveils New Brand Identity 4Health News:Lumension Expands Global Footprint, Extends Leadership in Endpoint Security and Unveils New Brand Identity 5Health News:SHOWUSA Launches: New Website Showcases Animated Maps of U.S. Facts and Figures 2Health News:New Enhanced Web Site and Catalog from Reid Supply 2Health News:New Enhanced Web Site and Catalog from Reid Supply 3Health News:Ther-Rx Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level 2
Adson Bone Rongeurs
Rongeur #18
Rongeur #4
Schell Rongeur
Medicine Products: